EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In situ and localized primary invasive pregnancy‐associated melanoma: Maternal and perinatal outcomes

Penelope Fotheringham iD, Nadom Safi, Linda K Martin, Serigne N Lo iD, Antoinette Anazodo, Marc Remond, Elizabeth A Sullivan

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Penelope Fotheringham und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia. Hauptthemen laut MEDLINE: Melanoma, Pregnancy Complications, Neoplastic, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Council NSW.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pregnancy‐associated melanoma (PAM) is melanoma diagnosed during pregnancy or the 12 months postpartum. There is long‐standing debate regarding the impact of pregnancy on melanoma prognosis. Previous studies have analysed pooled data from PAM diagnoses of all stages, so findings may not reflect outcomes associated with the diagnosis of in situ or localized PAM that are more commonly diagnosed than later stage PAM.

Objectives

To describe the incidence, perinatal and survival outcomes of in situ or localized primary invasive PAM (melanoma stages 0–II).

Methods

A population‐based retrospective cohort study in New South Wales (NSW), Australia was performed, comprising women who birthed between 1 January 1994 and 31 December 2013 and their babies, with mortality data available until September 2018. Women were grouped as gestational PAM (diagnosed with early‐stage melanoma during pregnancy), postpartum PAM (diagnosed with early‐stage melanoma within 1 year postpartum) or control (women who gave birth without a diagnosis of cancer). Perinatal outcomes were compared using generalized estimating equation models and mortality compared using Cox regression, Kaplan–Meier curves and the log‐rank test.

Results

In total, 1,785,876 pregnancies were identified, including 223 women (228 babies) with gestational PAM and 467 women (478 babies) with postpartum PAM. The incidence of in situ PAM increased 8.7% (95% CI: 4.0–13.5) per year between 2002 and 2013. The incidence of localized primary invasive PAM did not increase between 1994 and 2013. No significant maternal or neonatal morbidities were identified. Sixteen deaths were observed in women diagnosed with localized primary invasive PAM. The mortality rate for women with gestational PAM did not differ significantly from women with postpartum PAM (2.4/1000 person‐years vs. 1.6/1000 person‐years, p value = 0.394).

Conclusions

Diagnosis of early PAM in pregnancy or postpartum is not associated with significant adverse outcomes for women or their babies. Early diagnosis remains important to ensure appropriate treatment and positive outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaPregnancy Complications, NeoplasticSkin NeoplasmsHumansFemalePregnancyRetrospective StudiesAdultNew South WalesIncidenceInfant, NewbornYoung AdultNeoplasm InvasivenessPregnancy Outcome

Stichwörter der Autor:innen

melanomamorbiditymortalitypostpartumpregnancyskin neoplasm

Autor:innen und Institutionen

  • College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
  • Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
  • Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
  • School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, New South Wales, Australia.
  • Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia.
  • Faculty of Medicine and Health, University of New South Wales, Randwick, New South Wales, Australia.

ORCID-Profile: Penelope Fotheringham, Serigne N Lo

Förderung

  • Cancer Council NSW

Zitieren

APA

Fotheringham, P., Safi, N., Martin, L. K., Lo, S. N., Anazodo, A., Remond, M., & Sullivan, E. A. (2025). In situ and localized primary invasive pregnancy‐associated melanoma: Maternal and perinatal outcomes. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20894

Vancouver

Fotheringham P, Safi N, Martin LK, Lo SN, Anazodo A, Remond M, et al. In situ and localized primary invasive pregnancy‐associated melanoma: Maternal and perinatal outcomes. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20894

BibTeX
@article{Fotheringham2025,
  author = {Fotheringham, Penelope and Safi, Nadom and Martin, Linda K and Lo, Serigne N and Anazodo, Antoinette and Remond, Marc and Sullivan, Elizabeth A},
  title = {In situ and localized primary invasive pregnancy‐associated melanoma: Maternal and perinatal outcomes},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20894}
}
Kostenlos starten →